[1]李凤利,陈 伟,张 林.不同剂量沐舒坦在肺癌围术期的肺功能保护作用[J].医学信息,2018,31(07):128-130.[doi:10.3969/j.issn.1006-1959.2018.07.043]
　LI Feng-li,CHEN Wei,ZHANG Lin.Protective Effects of Different Doses of Ambroxol on Lung Function in Patients with Lung Cancer during Perioperative Period[J].Journal of Medical Information,2018,31(07):128-130.[doi:10.3969/j.issn.1006-1959.2018.07.043]
点击复制

不同剂量沐舒坦在肺癌围术期的肺功能保护作用()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年07期
页码:
128-130
栏目:
药物与临床
出版日期:
2018-04-01

文章信息/Info

Title:
Protective Effects of Different Doses of Ambroxol on Lung Function in Patients with Lung Cancer during Perioperative Period
文章编号:
1006-1959（2018）07-0128-03
作者:
李凤利1; 陈 伟2; 张 林3
1.青岛大学，山东 青岛 266003；2.临沂市中心医院神经外科，山东 临沂 276400； 3.青岛大学附属医院麻醉科，山东 青岛 266555
Author(s):
LI Feng-li1; CHEN Wei2; ZHANG Lin3
1.Qingdao University,Qingdao 266003,Shandong,China; 2.Department of Neurosurgery,Linyi Central Hospital,Linyi 276400,Shandong,China; 3.Department of Anesthesiology,Affiliated Hospital of Qingdao University,Qingdao 266555,Shandong,China
关键词:
不同剂量; 沐舒坦; 肺癌围术期; 肺功能保护
Keywords:
Key words：Different doses; Ambroxol; Perioperative lung cancer; Pulmonary function protection
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.07.043
文献标志码:
A
摘要:
目的 探讨不同剂量的沐舒坦在肺癌围术期的肺功能保护作用。方法 选取2015年1月~2017年1月在青岛大学附属医院胸外科进行手术治疗的90例非小细胞肺癌患者作为研究对象，随机分为小剂量组、中剂量组及大剂量组，每组30例。三组患者均在围手术期进行抗感染、营养支持等常规治疗的基础上，小剂量组给予沐舒坦200 mg/d持续静脉泵入，中剂量组给予沐舒坦500 mg/d持续静脉泵入，大剂量组给予沐舒坦800 mg/d持续静脉泵入，连续使用7 d后，比较三组患者术后肺部感染、肺不张等并发症发生率及术后1、3、5 d时的肺功能。结果 大剂量组患者的肺部感染率10.00%、肺不张发生率1.33%，低于中剂量组33.33%、66.67%，小剂量组53.33%、46.67%，三组差异有统计学意义（P＜0.05）。术后第3、5天时大剂量组患者的PaO2、PaO2/FiO2高于中剂量组和小剂量组，三组差异有统计学意义（P＜0.05）。结论 大剂量的沐舒坦在肺癌围手术期的肺功能保护作用优于中剂量、小剂量，中剂量的沐舒坦在肺癌围手术期的肺功能保护作用优于小剂量，即大剂量沐舒坦有助于降低肺部并发症，改善肺癌患者预后。
Abstract:
Abstract：Objective To investigate the protective effect of different doses of ambroxol on lung function in lung cancer perioperative period.Methods From January 2015 to January 2017,90 patients with non-small cell lung cancer(NSCLC)were randomly divided into three groups:small dose group,middle dose group and high dose group,30 cases in each group.All patients in the three groups were treated on the basis of routine treatment such as anti-infection and nutritional support during the perioperative period.In the low-dose group, continuous infusion of moxatan 200 mg/d was continued,and in the middle-dose group, mucosolvan 500 mg/d was continuously intravenously pumped.Large dose group received ambroxol 800 mg/d continuous intravenous infusion.After continuous use for 7 d,the incidence of postoperative complications such as pulmonary infection,atelectasis and lung function at 1,3,5 d after operation were compared between the three groups.Results The high-dose group had a pulmonary infection rate of 10.00% and a lung atelectasis rate of 1.33%,which was lower than the middle-dose group 33.33%,66.67% and the low-dose group 53.33%,46.67%,the difference between the three groups was statistically significant(P<0.05).At third,fifth days after the operation,the PaO2 and PaO2/FiO2 in the large dose group were higher than those in the middle dose group and the small dose group,and the difference between the three groups was statistically significant(P<0.05).Conclusion The protective effect of high dose ambroxol on lung function in lung cancer perioperative period was superior to that of middle dose,low dose,middle dose ambroxol was superior to small dose in lung cancer perioperative period.That is,high dose ambroxol can reduce pulmonary complications and improve the prognosis of lung cancer patients.

参考文献/References:

[1]黄庆,劳永光,张志辉.不同剂量氨溴索对肺叶切除术后并发症的影响[J].广东医科大学学报,2015(1):103-105. [2]袁丰.大剂量氨溴索静脉注射在微创肺癌根治术中的应用价值[J].中国生化药物杂志, 2016(5):95-97. [3]夏文超,韩兴鹏,韩洪利,等.不同剂量沐舒坦对肺癌术后患者的肺保护效果探讨[J].重庆医学,2012,41(17):1759-1760. [4]韩友奎,杨炳军,姜春阳,等.沐舒坦围手术期肺保护机制及应用策略[J].山东医药,2015(2):102-104. [5]刘行仁,王艳梅,杨雁.盐酸氨溴索注射液与术后肺癌患者并发症之间的量效关系[J].中国生化药物杂志,2016(7):173-175.

相似文献/References:

[1]高凤霞.沐舒坦雾化吸入联合静脉注射治疗新生儿肺炎的效果分析[J].医学信息,2018,31(04):12.[doi:10.3969/j.issn.1006-1959.2018.04.005]
　GAO Feng-xia.Effect of Atomization Inhalation of Ambroxol Combined with Intravenous Injection in the Treatment of Neonatal Pneumonia[J].Journal of Medical Information,2018,31(07):12.[doi:10.3969/j.issn.1006-1959.2018.04.005]
[2]花国辉.不同剂量阿托伐他汀治疗心梗后无症状心衰的疗效比较[J].医学信息,2020,33(04):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
　HUA Guo-hui.Comparison of the Effects of Different Doses of Atorvastatin on Asymptomatic Heart Failure After Myocardial Infarction[J].Journal of Medical Information,2020,33(07):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
[3]曾祥斌,邓嘉奇,张鹏飞,等.干扰素γ与沐舒坦联合雾化吸入治疗慢性支气管炎急性发作的临床疗效[J].医学信息,2024,37(20):123.[doi:10.3969/j.issn.1006-1959.2024.20.025]
　ZENG Xiangbin,DENG Jiaqi,ZHANG Pengfei,et al.Clinical Effect of Combined Interferon γ and Mucosolvan Aerosol Inhalation in the Treatment of Acute Attack of Chronic Bronchitis[J].Journal of Medical Information,2024,37(07):123.[doi:10.3969/j.issn.1006-1959.2024.20.025]
[4]李杨华.不同剂量瑞芬太尼用于无痛胃镜检查的有效性及安全性[J].医学信息,2024,37(23):54.[doi:10.3969/j.issn.1006-1959.2024.23.012]
　LI Yanghua.Efficacy and Safety of Different Doses of Remifentanil for Painless Gastroscopy[J].Journal of Medical Information,2024,37(07):54.[doi:10.3969/j.issn.1006-1959.2024.23.012]
[5]陈 添.不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果观察[J].医学信息,2025,38(13):98.[doi:10.3969/j.issn.1006-1959.2025.13.018]
　CHEN Tian.Observation on the Therapeutic Effect of Different Doses of Budesonide for Aerosol Inhalationon Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(07):98.[doi:10.3969/j.issn.1006-1959.2025.13.018]
[6]樊 蓓,刘 倩.不同剂量利伐沙班治疗老年心力衰竭合并房颤患者的临床效果及安全性对比[J].医学信息,2025,38(13):142.[doi:10.3969/j.issn.1006-1959.2025.13.028]
　FAN Bei,LIU Qian.Comparison of Clinical Efficacy and Safety of Different Doses of Rivaroxaban in the Treatmentof Elderly Patients with Heart Failure and Atrial Fibrillation[J].Journal of Medical Information,2025,38(07):142.[doi:10.3969/j.issn.1006-1959.2025.13.028]

更新日期/Last Update: 2018-04-01